Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-10-23 Declaration of Voting R…
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Updates
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official communication from Orchid Pharma Limited to stock exchanges regarding the initiation of a postal ballot process for shareholder approval. It details the resolution to appoint a new Non-Executive Director, the voting process, cut-off dates, and instructions for shareholders to register their email addresses for remote e-voting. There are no financial statements, earnings data, or detailed management discussion. The document is an announcement about a shareholder voting process rather than the voting results or the meeting itself. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained results, but here it is about initiating the postal ballot process. It is not a proxy solicitation or information statement (PSI) because it does not provide full meeting materials or request votes directly but informs about the process. It is not a regulatory filing (RNS) fallback because it is a specific announcement about shareholder voting procedures. The best fit is Declaration of Voting Results & Voting Rights Announcements (DVA) as it relates to shareholder voting rights and processes, even though it is about initiation rather than results, this category covers voting rights announcements broadly. Confidence is high due to clear keywords like 'Postal Ballot Process', 'shareholders’ approval', 'voting rights', and 'remote e-voting'.
2023-10-23 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing the appointment of a new Additional Director, Mr. Arjun Dhanuka. It includes details about the appointment, terms, and brief profile of the director. There is no financial data, earnings information, or report attached. The content clearly relates to a change in the company's board of directors. Therefore, this fits the category of Board/Management Information (MANG). The document length is 4610 characters, which is sufficient for a detailed announcement but not a full report.
2023-10-20 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a compliance certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended September 30, 2023. It is a certificate from the Registrar and Share Transfer Agent confirming dematerialization and listing compliance. The document is short (3380 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and regulatory announcements that do not fit other specific categories.
2023-10-12 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice from Orchid Pharma Limited informing about the closure of the trading window pursuant to SEBI regulations ahead of the announcement of un-audited financial results for the quarter and half year ended September 30, 2023. It does not contain any financial data or results itself, nor does it provide detailed financial analysis or report. The document is a regulatory announcement related to insider trading compliance and timing of financial results disclosure. Given the short length (2112 characters) and the nature of the content, this is an announcement related to regulatory compliance rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2023-09-29 English
Updates
Legal Proceedings Report Classification · 95% confidence The document is a disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details pending material litigations and disputes involving the company, Orchid Pharma Limited. The content focuses on legal proceedings, claims, and penalties, with no financial statements or earnings data. The document is an update on legal matters rather than a full legal proceeding report or financial report. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length (6864 characters) supports it being a substantive disclosure rather than a brief announcement or certification.
2023-09-27 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about a scheduled investor roadshow event for Orchid Pharma Limited. It is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers disclosures about events or information that may affect the company. The document does not contain any financial data, report, or detailed presentation, nor does it announce voting results, management changes, or legal proceedings. It is essentially a regulatory announcement informing about an upcoming event. Given the short length (1597 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.